Auspex rises on Phase III Huntington's data success
This article was originally published in Scrip
Executive Summary
Shares in La Jolla-based Auspex Pharmaceuticals leapt as much as 65% to reach $41.50 on 16 December after it announced positive top-line Phase III data for its First HD study of SD-809 for the treatment of chorea associated with Huntington's disease (HD). A US NDA filing is planned for mid-2015.